Wang Bo, Janamnuaysook Rena, MacDonell Karen, Rongkavilit Chokechai, Schieber Elizabeth, Naar Sylvie, Phanuphak Nittaya
Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States.
Institute of HIV Research and Innovation, Center of Excellence in Transgender Health, Chulalongkorn University, Bangkok, Thailand.
JMIR Res Protoc. 2023 Sep 4;12:e46435. doi: 10.2196/46435.
Young men who have sex with men (YMSM) are the fastest-growing HIV-positive population worldwide. Thailand has the highest adult HIV seroprevalence in Asia; over 25% of men having sex with men in Bangkok are HIV positive. Pre-exposure prophylaxis (PrEP) is an efficacious HIV prevention strategy recommended for all at-risk individuals. PrEP is highly effective when taken as prescribed, but PrEP utilization rate has been low, and adherence is often inadequate.
We propose to develop and pilot a multicomponent, technology-based intervention to promote motivation to begin PrEP ("uptake") and sustained adherence to PrEP among HIV-negative Thai YMSM. We will adapt an existing 2-session technology-delivered, motivational interviewing-based intervention to focus on PrEP use in YMSM in Thailand. The resulting intervention is called the Motivational Enhancement System for PrEP Uptake and Adherence (MES-PrEP). We will also develop motivational text messaging (MTM) to send two-way motivational messages to promote PrEP use.
The proposed study includes 3 phases. Phase 1 includes in-depth interviews with HIV-negative Thai YMSM and providers to explore barriers and facilitators of PrEP initiation and adherence, aiming to inform intervention content. Phase 2 consists of adapting and beta-testing MES-PrEP and MTM for functionality and feasibility using a youth advisory board of Thai YMSM. In Phase 3, we will conduct a pilot randomized controlled trial to evaluate the feasibility, acceptability, and preliminary efficacy of MES-PrEP and MTM to increase PrEP uptake and adherence among Thai YMSM. A total of 60 HIV-negative Thai YMSM who have not started PrEP and 60 YMSM who are on PrEP but not adherent to it will be randomized 2:1 to receive MES-PrEP and MTM (n=40) or standard PrEP counseling (n=20). The feasibility and acceptability of the intervention will be assessed through usage patterns and the System Usability Scale. The preliminary impact will be assessed by evaluating the proportion of PrEP initiation and level of adherence to PrEP. Participants will complete the assessments at baseline and at 1-, 3-, and 6-month postintervention. Biomarkers of adherence to PrEP and biomarkers of HIV and sexually transmitted infections will be collected.
Recruitment for this study began in January 2022 for phase 1. Qualitative interviews were completed with 30 YMSM and 5 clinical providers in May 2022. Phase 3, the pilot feasibility and acceptability trial, began in July 2023. Upon project completion, we shall have developed a highly innovative mobile health intervention to support YMSM using PrEP, which will be ready for testing in a larger efficacy trial.
This study addresses a critical problem (ie, high HIV incidence and low PrEP use) among Thai YMSM. We are developing 2 potentially synergistic technology-based, theory-driven interventions aimed at maximizing PrEP use. The proposed project has the potential to make significant contributions to advancing HIV prevention research and implementation science.
ClinicalTrials.gov NCT05243030; https://clinicaltrials.gov/ct2/show/NCT05243030.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/46435.
男男性行为的年轻男性(YMSM)是全球范围内感染艾滋病毒人数增长最快的群体。泰国是亚洲成年人艾滋病毒血清阳性率最高的国家;曼谷超过25%的男男性行为者感染了艾滋病毒。暴露前预防(PrEP)是一项针对所有高危人群推荐的有效艾滋病毒预防策略。按规定服用时,PrEP非常有效,但PrEP的利用率一直很低,且依从性往往不足。
我们提议开发并试点一种多组分、基于技术的干预措施,以提高艾滋病毒阴性的泰国YMSM开始使用PrEP(“采用率”)的动机,并持续坚持使用PrEP。我们将改编现有的基于动机性访谈的两阶段技术干预措施,使其专注于泰国YMSM使用PrEP的情况。由此产生的干预措施称为PrEP采用和依从性动机增强系统(MES-PrEP)。我们还将开发动机性短信(MTM),发送双向动机性信息以促进PrEP的使用。
拟议的研究包括3个阶段。第1阶段包括对艾滋病毒阴性的泰国YMSM和提供者进行深入访谈,以探索开始使用PrEP和坚持使用PrEP的障碍及促进因素,旨在为干预内容提供信息。第2阶段包括使用泰国YMSM青年咨询委员会对MES-PrEP和MTM进行功能和可行性方面的改编及测试。在第3阶段,我们将进行一项试点随机对照试验,以评估MES-PrEP和MTM在增加泰国YMSM使用PrEP及坚持使用PrEP方面的可行性、可接受性和初步疗效。共有60名尚未开始使用PrEP的艾滋病毒阴性泰国YMSM和60名正在使用PrEP但未坚持使用的YMSM将按2:1随机分组,分别接受MES-PrEP和MTM(n = 40)或标准PrEP咨询(n = 20)。将通过使用模式和系统可用性量表评估干预措施的可行性和可接受性。将通过评估PrEP开始使用的比例和PrEP的依从水平来评估初步影响。参与者将在基线以及干预后1个月、3个月和6个月完成评估。将收集PrEP依从性的生物标志物以及艾滋病毒和性传播感染的生物标志物。
本研究的第1阶段招募工作于2022年1月开始。2022年5月完成了对30名YMSM和5名临床提供者的定性访谈。第3阶段,即试点可行性和可接受性试验,于2023年7月开始。项目完成后,我们将开发一种高度创新的移动健康干预措施,以支持YMSM使用PrEP,该措施将准备好在更大规模的疗效试验中进行测试。
本研究解决了泰国YMSM中的一个关键问题(即艾滋病毒高发病率和PrEP低使用率)。我们正在开发2种可能具有协同作用的基于技术、理论驱动的干预措施,旨在最大限度地提高PrEP的使用率。拟议的项目有可能为推进艾滋病毒预防研究和实施科学做出重大贡献。
ClinicalTrials.gov NCT05243030;https://clinicaltrials.gov/ct2/show/NCT05243030。
国际注册报告识别码(IRRID):DERR1-10.2196/46,435。